What is Refocus Group?
Founded in 1994, Refocus Group is a medical device enterprise dedicated to the research and development of advanced treatments for human vision disorders. The company is primarily recognized for its VisAbility Micro-Insert System, an investigational medical device currently undergoing clinical trials for the binocular treatment of presbyopia. By focusing on the underlying mechanics of age-related vision loss, the firm provides a unique value proposition to both eye care professionals and patients seeking non-invasive alternatives to traditional corrective lenses. Its market position is defined by a deep integration of clinical science and engineering, aimed at addressing the unmet needs of an aging global population.
How much funding has Refocus Group raised?
Refocus Group has raised a total of $15.3M across 2 funding rounds:
Unspecified
$15M
Debt
$350K
Unspecified (2016): $15M with participation from WP Global Partners and MedCare Investment Funds
Debt (2020): $350K led by PPP
Key Investors in Refocus Group
WP Global Partners
WP Global Partners focuses on producing value by backing enterprises that are essential to U.S. employment and economic growth through a hybrid investment strategy.
MedCare Investment Funds
MedCare manages approximately $1 billion in assets, specializing in the medical and healthcare services industry with a focus on long-term business growth.
PPP
Public-Private Partnership
What's next for Refocus Group?
With the recent influx of capital, Refocus Group is poised to accelerate its clinical trial milestones and operational readiness. The strategic deployment of these funds will likely focus on finalizing the regulatory pathway for the VisAbility Micro-Insert System, ensuring that the company can transition from the investigational phase to commercialization. As the firm moves forward, the emphasis will remain on validating the efficacy and safety of its technology, while simultaneously strengthening its intellectual property portfolio. Investors are closely monitoring the company's progress, as successful clinical outcomes could significantly disrupt the current standard of care for presbyopia, offering a scalable solution in a high-demand healthcare segment.
See full Refocus Group company page
